Chronic fatigue syndrome (CFS) is a debilitating and complex disorder characterized by unexplained fatigue not improved by rest, that lasts longer than 6 months, and that may be aggravated by physical or mental activity. In CFS, fatigue is also characterized by rheumatological, and neuropsychiatric symptoms such as joint pain, aching or stiff muscles, concentration and memory problems, sleep disruption, sore throat, headaches and so on.1,2 In 2011, the International Consensus Criteria have been defined by the Canadian definition released in 2003;3 however, at present, no laboratory tests can be used to objectively diagnose CFS. Therefore, the diagnosis of CFS remains a clinical endeavor and can be made after the exclusion of medical conditions that may explain the prolonged fatigue as well as a number of psychiatric diagnoses (for example, bipolar disorder, eating disorders, psychotic disorders and melancholic depression).

This difficulty in defining CFS, due to the lack of diagnostic markers, complicates epidemiological studies. Prevalence varies from as low as 0.2% to as high as 6.41%,4,5 with an incidence rate of 0.43% for women compared to 0.18% for men.6–8

Fatigue is a prominent symptom in CFS patients; however, many of the observed abnormalities could entail an energy deficiency and explain the peculiar fatigue.9 Moreover, it has often been suggested that CFS may have a genetic predisposition; therefore, twin studies supply the best account for helping in diagnosis. Furthermore, the identification of biomarkers present in particular subgroups of CFS patients may help in shedding light upon the complex entity of CFS. Moreover, it could help in developing tailored treatments.

Another area of investigation is the likely connection of CFS with defective mitochondrial function. In a previous work, we investigated the proteomic salivary profile in a couple of monozygotic twins discordant for CFS. Following this work, we analyzed mitochondrial proteins in the same couple of twins. Nano-liquid chromatography electrospray ionization mass spectrometry (nano-LC-MS) was used to study the mitochondria extracted from platelets of the twins. Subsequently, we selected three proteins that were validated using western blot analysis in a big cohort of subjects (n = 45 CFS; n = 45 healthy), using whole saliva (WS). The selected proteins were as follows:aconitate hydratase (ACON), ATP synthase subunit beta (ATPB) and malate dehydrogenase (MDHM). Results for ATPB and ACON confirmed their upregulation in CFS. However, the MDHM alteration was not confirmed. Thereafter, seeing the great variability of clinical features of CFS patients, we decided to analyze the expression of our proteins after splitting patients according to clinical parameters. For each marker, the values were actually higher in the group of patients who had clinical features similar to the ill twin. In conclusion, these results suggest that our potential markers could be one of the criteria to be taken into account for helping in diagnosis. Therefore, the identification of biomarkers present in particular subgroups of CFS patients may help in shedding light upon the complex entity of CFS. Moreover, it could help in developing tailored treatments.

TRANSLATIONAL PSYCHIATRY

**Original Article**

**Bottom-up proteomics suggests an association between differential expression of mitochondrial proteins and chronic fatigue syndrome**

F Ciregia1, L Kollipara2, L Giusti1, RP Zahedi2, C Giacomelli3, MR Mazzoni1, G Giannaccini1, P Scarpellini4, A Urbani5,6, A Sickmann2,7,8, A Lucacchini1 and L Bazzichi3

**INTRODUCTION**

Chronic fatigue syndrome (CFS) is a debilitating and complex disorder characterized by unexplained fatigue not improved by rest, that lasts longer than 6 months, and that may be aggravated by physical or mental activity. In CFS, fatigue is also characterized by rheumatological, and neuropsychiatric symptoms such as joint pain, aching or stiff muscles, concentration and memory problems, sleep disruption, sore throat, headaches and so on.1,2 In 2011, the International Consensus Criteria have been defined to identify CFS by revising the Canadian definition released in 2003;3 however, at present, no laboratory tests can be used to objectively diagnose CFS. Therefore, the diagnosis of CFS remains a clinical endeavor and can be made after the exclusion of medical conditions that may explain the prolonged fatigue as well as a number of psychiatric diagnoses (for example, bipolar disorder, eating disorders, psychotic disorders and melancholic depression).

This difficulty in defining CFS, due to the lack of diagnostic markers, complicates epidemiological studies. Prevalence varies from as low as 0.2% to as high as 6.41%,4,5 with an incidence rate of 0.43% for women compared to 0.18% for men.6–8

Fatigue is a prominent symptom in CFS patients; however, many of the observed abnormalities could entail an energy deficiency and explain the peculiar fatigue.9 Moreover, it has often been suggested that CFS may have a genetic predisposition; therefore, twin studies supply the best account for helping in diagnosis. Furthermore, the identification of biomarkers present in particular subgroups of CFS patients may help in shedding light upon the complex entity of CFS. Moreover, it could help in developing tailored treatments.

Another area of investigation is the likely connection of CFS with defective mitochondrial function. In a previous work, we investigated the proteomic salivary profile in a couple of monozygotic twins discordant for CFS. Following this work, we analyzed mitochondrial proteins in the same couple of twins. Nano-liquid chromatography electrospray ionization mass spectrometry (nano-LC-MS) was used to study the mitochondria extracted from platelets of the twins. Subsequently, we selected three proteins that were validated using western blot analysis in a big cohort of subjects (n = 45 CFS; n = 45 healthy), using whole saliva (WS). The selected proteins were as follows: aconitate hydratase (ACON), ATP synthase subunit beta (ATPB) and malate dehydrogenase (MDHM). Results for ATPB and ACON confirmed their upregulation in CFS. However, the MDHM alteration was not confirmed. Thereafter, seeing the great variability of clinical features of CFS patients, we decided to analyze the expression of our proteins after splitting patients according to clinical parameters. For each marker, the values were actually higher in the group of patients who had clinical features similar to the ill twin. In conclusion, these results suggest that our potential markers could be one of the criteria to be taken into account for helping in diagnosis. Furthermore, the identification of biomarkers present in particular subgroups of CFS patients may help in shedding light upon the complex entity of CFS. Moreover, it could help in developing tailored treatments.

**OPEN**

Citation: Transl Psychiatry (2016) 6, e904; doi:10.1038/tp.2016.184; published online 27 September 2016

**TOPIC: CHRONIC FATIGUE SYNDROME**

**ORIGINAL ARTICLE**

Bottom-up proteomics suggests an association between differential expression of mitochondrial proteins and chronic fatigue syndrome

F Ciregia1, L Kollipara2, L Giusti1, RP Zahedi2, C Giacomelli3, MR Mazzoni1, G Giannaccini1, P Scarpellini4, A Urbani5,6, A Sickmann2,7,8, A Lucacchini1 and L Bazzichi3

Chronic fatigue syndrome (CFS) is a debilitating and complex disorder characterized by unexplained fatigue not improved by rest, that lasts longer than 6 months, and that may be aggravated by physical or mental activity. In CFS, fatigue is also characterized by rheumatological, and neuropsychiatric symptoms such as joint pain, aching or stiff muscles, concentration and memory problems, sleep disruption, sore throat, headaches and so on.1,2 In 2011, the International Consensus Criteria have been defined to identify CFS by revising the Canadian definition released in 2003;3 however, at present, no laboratory tests can be used to objectively diagnose CFS. Therefore, the diagnosis of CFS remains a clinical endeavor and can be made after the exclusion of medical conditions that may explain the prolonged fatigue as well as a number of psychiatric diagnoses (for example, bipolar disorder, eating disorders, psychotic disorders and melancholic depression).

This difficulty in defining CFS, due to the lack of diagnostic markers, complicates epidemiological studies. Prevalence varies from as low as 0.2% to as high as 6.41%,4,5 with an incidence rate of 0.43% for women compared to 0.18% for men.6–8

Fatigue is a prominent symptom in CFS patients; however, many of the observed abnormalities could entail an energy deficiency and explain the peculiar fatigue.9 Moreover, it has often been suggested that CFS may have a genetic predisposition; therefore, twin studies supply the best account for helping in diagnosis. Furthermore, the identification of biomarkers present in particular subgroups of CFS patients may help in shedding light upon the complex entity of CFS. Moreover, it could help in developing tailored treatments.

Another area of investigation is the likely connection of CFS with defective mitochondrial function. In a previous work, we investigated the proteomic salivary profile in a couple of monozygotic twins discordant for CFS. Following this work, we analyzed mitochondrial proteins in the same couple of twins. Nano-liquid chromatography electrospray ionization mass spectrometry (nano-LC-MS) was used to study the mitochondria extracted from platelets of the twins. Subsequently, we selected three proteins that were validated using western blot analysis in a big cohort of subjects (n = 45 CFS; n = 45 healthy), using whole saliva (WS). The selected proteins were as follows: aconitate hydratase (ACON), ATP synthase subunit beta (ATPB) and malate dehydrogenase (MDHM). Results for ATPB and ACON confirmed their upregulation in CFS. However, the MDHM alteration was not confirmed. Thereafter, seeing the great variability of clinical features of CFS patients, we decided to analyze the expression of our proteins after splitting patients according to clinical parameters. For each marker, the values were actually higher in the group of patients who had clinical features similar to the ill twin. In conclusion, these results suggest that our potential markers could be one of the criteria to be taken into account for helping in diagnosis. Furthermore, the identification of biomarkers present in particular subgroups of CFS patients may help in shedding light upon the complex entity of CFS. Moreover, it could help in developing tailored treatments.
our results highlighted the involvement of inflammatory response in CFS pathogenesis. Following the encouraging results obtained with this preliminary study, we sought to improve our knowledge about mechanisms of CFS by analyzing mitochondrial proteins in the same couple of monozygotic twins discordant for CFS. The expectation was that our findings could be able to provide evidence of a mitochondrial role in CFS pathogenesis.

With this purpose, we isolated mitochondria from platelets. Platelets are circulating blood cells that are essential not only in hemostasis and coagulation but also in innate and adaptive immunity. Platelets have functionally active mitochondria, whose involvement in cell physiology and in pathological conditions has been increasingly demonstrated. The recent assessments of mitochondrial function in platelets offer several advantages for diagnostic purposes, such as their abundance in peripheral blood, the relative ease of obtaining platelets, their limited complexity, and the considerable number of mitochondria contained in platelets and the ability to make repeated measurements for each patient.

Platelets have already been used in investigations of mitochondrial involvement in some disorders, for example, in sepsis, neurodegenerative diseases or diabetes. However, these studies were limited to mitochondria DNA analysis and electron transfer activities, whereas no investigation has been performed on the total mitochondrial protein content. Therefore, we analyzed with nano-liquid chromatography electrospray ionization mass spectrometry (nano-LC-MS) the mitochondria extracted from platelets of the same couple of monozygotic twins discordant for CFS who have been the subjects of our previous work. Subsequently, the most promising biomarkers were validated by western blot analysis in a big cohort of patients, using whole saliva (WS), whose sampling is a noninvasive, simple, safe and stress-free procedure that can be easily applied to large groups of subjects. Seeing the vast heterogeneity of the disease, the aim was to suggest biomarkers to stratify CFS cases, rather than selecting some biomarkers for identifying CFS. This can help to customize intervention.

MATERIALS AND METHODS

Study design

This translational case–control study was subdivided into three different steps. The first ‘discovery’ phase was aimed at characterizing the mitochondrial proteomic profile of a patient suffering from CFS in comparison with his healthy monozygotic twin. This purpose was achieved by using a proteomics approach: nano-LC-MS. The second ‘exploratory’ phase was aimed at investigating the changing proteins; we applied the Ingenuity Pathway Analysis (IPA) Knowledge base. This platform enabled to visualize the potential interactions between the identified biomarker signatures in mitochondria helping us to select some candidates for the ‘validation’ phase. Selected proteins were first searched in WS of the twin brothers and, once the differences have been confirmed, the validation was widened to a larger number of patients and controls. Finally, we have amplified our analysis looking closely at clinical data, with the specific aim to investigate how the biomarkers correlate with patients’ clinical parameters. This leads us to identify mitochondrial proteins useful in subtyping patients with CFS.

Patients

The recruitment of the subjects was managed by the Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. This study has been approved by the local Ethics Committee, and an informed consent was obtained for diagnostic or clinical purposes.

The twins of the previous study were enrolled to collect peripheral venous blood samples for the purpose of ‘discovery’ phase, and saliva for the validation. Samples, both blood and WS, were collected three times from the twins. In addition, a total of 45 patients affected by CFS were consecutively recruited for the ‘validation’ phase; mean age 38.6 ± 11.9 years (mean ± s.d.; M ± s.d.; Table 1). Forty-five healthy subjects, with similar mean age (36.4 ± 10.9, M ± s.d.; 25 females, 20 males) and demographic characteristics, were included as controls (see Supplementary Methods 1). The patients were classified based on the classification criteria of Fukuda et al.

The patients performed a rheumatologic visit with routine clinical evaluation of medical history. The subjects completed the Fibromyalgia Impact Questionnaire (FIQ), in which pain and fatigue severity were assessed with 10-cm Visual Analog Score Scale (VAS) and short form-36. Fatigue was assessed also by means of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT). We considered the VAS from the FIQ asking whether the patient felt rested upon awaking during the last week. In order to assess the presence of psychiatric concomitant disorders, patients had a psychiatric evaluation based on the administration of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, axis-I disorders.

To better classify the subjects the following hematocellular parameters were evaluated:

- Immunochemical parameters: antinuclear antibodies, extractable nuclear antigen antibodies, rheumathoid factor (Ra test) and anticardiolipin antibodies.
- Hormone profile: cortisole and adrenocorticotropic hormone, serotonin, growth hormone, insulin-like growth factor-1 and vitamin D3.
- Cytokine profile: tumor necrosis factor (TNF)-α, interferon (IFN)-γ, interleukin (IL)-6, IL-10, IL-2, IL-8 and IL-1β.

Table 1 summarizes clinical data.

WS collection

Salivary samples were collected from patients (n = 45) and controls (n = 45) with a saliva collector sponge (Surescreen Diagnostics, Derby, UK). WS samples were collected early in the morning (between 0800 and 1100 hours) according to a standard protocol. No evidence of oral pathologies or inflammatory processes was observed. The collected saliva was immediately centrifuged at 17 000 g for 20 min at 4 °C to yield clear samples. The resulting supernatants were stored at −80 °C. Protein amounts of samples were determined using the Bio-Rad DC-protein assay (Bio-Rad, Hercules, CA, USA). Bovine serum albumin was used as a standard.

Platelet collection and mitochondrial enrichment

Blood samples were drawn from an antecubital vein using a 19-gauge needle and the first 2.5 ml were discarded. All samples were collected in Vacutainer tubes (Becton Dickinson, San Jose, CA, USA), containing 3.8% sodium citrate as anticoagulant.

Peripheral venous blood sample (25 ml) was drawn from the subjects and placed in proper collecting tubes with heparin. The samples were immediately processed to obtain platelets. Blood was centrifuged for 15 min at 300 g to obtain a platelet-rich plasma and a pellet-containing red cells, granulocytes and lymphocytes. Platelets were precipitated from platelet-rich plasma by centrifugation at 3000 g for 10 min and resuspended in 0.9% NaCl; an aliquot of 300 μl was stored for normalization, whereas the remaining was used for mitochondrial enrichment.

Isolation of mitochondrial fractions from human platelets was performed by differential centrifugation. The platelets were centrifuged for 10 min at 3000 g. A volume of cold lysis buffer (10 mM Tris-HCl pH 7.6), depending on the size of the pellet, was added and kept 7 min on ice stirring occasionally. After centrifugation for 10 min at 1000 g we obtained unbroken cells (P1). The supernatant, containing mitochondria, was immediately centrifuged for 20 min at 9000 g obtaining mitochondrial fraction M1. M1 was further resuspended in cold lysis buffer, and kept for 7 min on ice stirring occasionally. After a centrifugation for 10 min at 1000 g, the resulting supernatant was immediately centrifuged for 20 min at 9000 g obtaining mitochondrial fraction M2. M1 and M2 were immediately resuspended in cold buffer (10 mM Tris-HCl pH 7.4, 2 mM EDTA, 250 mM Sucrose) and combined. Protein amounts were determined using the Bio-Rad DC-protein assay (Bio-Rad). Bovine serum albumin was used as a standard.

The integrity of mitochondria was assayed by measuring the activity of cytochrome oxidase. Western blot (WB) analysis was performed to evaluate the purity of the mitochondria as described in Supplementary Method 2. Blood was collected three times, and mitochondria obtained from each
Table 1. Demographics, questionnaire score, hematochemical parameters and psychiatric evaluation of CFS patients

| Demographics          | CFS twin | CFS patients (n = 45) | Mean ± s.d. | Min–max |
|-----------------------|----------|-----------------------|-------------|---------|
| Sex (M/F)             | M        | 22/23                 | 38.6 ± 11.9 | 19–63   |
| Age (y)               | 41       | 7.2 ± 5.6             | 5.6 ± 4.6   | 1–19    |

| Duration of symptoms (y) | 33       | 3.3 ± 0.3             | 2.7 ± 0.6   | 2–4     |
| Latency of diagnosis (y) | 7        | 10 ± 3.3              | 8 ± 1.5     | 6–12    |

| Questionnaire       | CFS twin | Min–max | Hematochemical parameters | CFS twin | Min–max |
|---------------------|----------|---------|---------------------------|----------|---------|
| FIQ                 | 61.2     | 55 ± 21 | TNF-α                     | 18.1     | 9.8 ± 4.3 | 2.1–29 |
| VAS pain            | 3        | 3.4 ± 3.1| IFN-γ                     | 0.2      | 1.6 ± 3.6 | 0–19.3|
| VAS fatigue         | 8        | 7.7 ± 2 | IL-6                      | 2        | 1.8 ± 2.3 | 0.1–0.8 |
| VAS sleep           | 8        | 7.4 ± 2 | IL-10                     | 2        | 3.6 ± 3.3 | 0.3–13 |
| FACIT               | 26       | 30 ± 10 | IL-2                      | 10       | 31 ± 38   | 2–152  |
| SF-36               |          |         |                           |          |          |
| Physical functioning | 50       | 59 ± 19 | IL-8                      | 0.3      | 0.4 ± 0.01 | 0.2–0.6 |
| Role physical       | 0        | 15 ± 25 | IL-1β                     | 0.2      | 0.7 ± 1.8 | 0.2–9.9 |
| Bodily pain         | 84       | 49 ± 33 | Cortisone                 | 18       | 19 ± 5.5  | 10–29.7 |
| General health status | 10    | 36 ± 14 | ACTH                      | 13       | 32 ± 21   | 10–84  |
| Vitality            | 25       | 32 ± 27 | 5-HT                      | 88       | 180 ± 187 | 16–887 |
| Social activities    | 25       | 32 ± 27 | GH                        | 0        | 0 ± 0.7   | 0–2.3  |
| Mental health        | 66       | 46 ± 42 | IGF-1                     | 190      | 339 ± 144 | 139–607 |
|                      | 64       | 61 ± 19 | VIt D3                    | 25       | 16 ± 7.7  | 1.5–38  |

| Psychiatric evaluation | CFS twin | CFS patients (n = 45) | % | Psychiatric comorbidities |
|------------------------|----------|-----------------------|---|--------------------------|
| Total                  | 21/45    | (47%)                 |   | + Bipolar disorder II    |
| Panic disorder         | 13/45    | (29%)                 |   | + Eating disorder        |
| Bipolar disorder II    | 4/45     | (9%)                  |   |                          |
| Major depression       | 3/45     | (7%)                  |   |                          |
| Eating disorder        | 1/45     | (2%)                  |   |                          |

| Abbreviations: ACTH, adrenocorticotropic hormone; CFS, chronic fatigue syndrome; F, female; FACIT, Functional Assessment of Chronic Illness Therapy-Fatigue Scale; FIQ, Fibromyalgia Impact Questionnaire; IGF-1, insulin-like growth factor-1; GH, growth hormone; 5-HT, serotonin; IL, interleukin; M, male; SF-36, short form-36; TNF, tumor necrosis factor; VAS, Visual Analog Score Scale; VIt D3, vitamin D3; y, year. |
windows from 0 to 90 min and 300–1500 m/z with charge states +2, +3 and +4 were considered for peptide statistics, analysis of variance and principal component analysis. Spectra were exported as peak lists, searched against a concatenated target/decoy version of the human Uniprot database, (downloaded on 11 December 2013, containing 20 273 target sequences) using Mascot 2.4 (Matrix Science, Boston, MA, USA). Trypsin was selected as enzyme with a maximum of two missed cleavage sites, carbamidomethylation of Cys was set as fixed and oxidation of Met was selected as variable modification. MS and MS/MS tolerances were set to 10 p.p.m. and 0.5 Da, respectively. Peptide Shaker version 0.28.0 (ref. 38) was used for processing peptide-spectrum matches obtained from Mascot and filtering the results at a false discovery rate of 1% on the peptide-spectrum match, peptide and protein level. Results were exported using the advanced Peptide Shaker features, allowing direct re-import of the quality-controlled data into Progenesis. Only proteins that were quantified with ≥2 unique peptides were considered for further analysis. The signal intensities of each protein present in the mitochondrial fraction were normalized on the total content of the same proteins obtained from the analysis of total platelets.

Signaling pathway analysis
Proteins differentially expressed were functionally analyzed through the use of QIAGEN’s IPA (Ingenuity System, QIAGEN, Redwood City, CA, USA) to select candidates for validation. All differently expressed proteins with a fold variation in CFS greater than 2.0 with respect to control were included in bioinformatic analysis to identify molecular functions most strongly associated with the protein list. Supplementary Method 3 gives more details about this analysis.

WB for validation
To validate the expression changes in WS, we used WB analysis. The selected proteins were as follows:aconitate hydratase (ACON), ATP synthase subunit beta (ATPB) and malate dehydrogenase (MDHM). For ACON and MDHM, we loaded 30 μg of proteins and 10 μg for ATPB. Proteins were resolved by 12% SDS-PAGE gels and transferred on nitrocellulose membranes as previously described. ACON and MDHM antibodies have been used at 1:200 dilution (Cell Signaling Technology, Danvers, MA, USA), whereas the ATPB antibody (Santa Cruz Biotechnology, Dallas, TX, USA) has been used at 1:200 dilution. A horseradish peroxidase-conjugated goat anti-rabbit (Stressgen, Farmingdale, NY, USA) was used as a secondary antibody at 1:10,000 dilution. Immunoblots were developed using the enhanced chemiluminescence detection system. The chemiluminescent images were acquired using LAS4010 (GE Health Care, Uppsala, Sweden). The antigen-specific bands were quantified using the ImageQuant-G software. In order to normalize the optical density of immune-reactive bands, the optical density of total proteins was calculated. Therefore, immediately after WB, the membranes were stained with 1 mM RuBP as previously described.

Statistical analysis
All data are presented as mean ± s.e.m. Comparisons between groups were performed using the Mann–Whitney U-test for non-normal data. A P-value < 0.05 was considered significant. Linear regression analysis was used to determine the correlation among levels of different biomarkers. Logistic regression was used to determine the weight given to each marker and then to calculate a specific formula to provide a combined risk index. To estimate whether this marker combination might increase the marker’s performance in CFS diagnosis, receiver operating characteristic (ROC) curves were plotted, and the areas under curves (AUCs) were calculated with their 95% confidence intervals using standard techniques to evaluate sensitivity and specificity of each marker and their combination. Statistical analyses were performed with R (version 3.3.0) and SPSS (SPSS/PC Statistical Package for the Social Science, update for 10.1, SPSS, Chicago, IL, USA, 2000).

RESULTS
Proteomic analysis
In order to profile the mitochondrial proteins in CFS, we purified mitochondria from platelets of the same couple of monozygotic twins, discordant for CFS, which was investigated in our previous work.20 To evaluate the quality of the isolated mitochondria, enzymatic assay and WB analysis were employed (see Supplementary Results 1), confirming that we reached satisfactory mitochondrial enrichment (Supplementary Figure). We obtained a mitochondrial fraction of 450 μg of proteins starting roughly from 5 × 10⁹ platelets.

Moreover, with the aim to overcome the limit of reproducibility in the mitochondrial preparation, experiments were performed three times. Mitochondria obtained from each of the three experiments were pooled together and analyzed in triplicate. The protein composition of mitochondria was analyzed by nano-LC-MS and a differential analysis between CFS patient and his healthy brother was performed. Overall, we identified 1007 proteins with a number of peptides used for quantitation ≥2. Out of 1007 proteins detected using the label-free approach, 194 mitochondrial proteins were significantly modified in CFS. Among these 194 proteins, 41 had a fold variation in CFS with respect to control greater than 2.0, 34 were upregulated in CFS and 7 were downregulated. Table 2 contains data of these 41 proteins. Table containing the remaining 153 proteins is supplied as Supplementary Table S1.

These 41 proteins were included in the analysis with IPA. Each identified protein was converted to its gene and mapped to its corresponding gene object in the IPA knowledge base. We utilized IPA to retrieve the known functions of each protein. As one protein may have multiple functions, we selected the functions with the highest statistical significance. The first three top-ranked biological functions were as follows: metabolism of isocitric acid (P-value = 1.83e^-08), metabolism of NADH (P-value = 4.00e^-07) and metabolism of nucleic-acid component or derivative (P-value = 8.15e^-27). These significantly over-represented categories, together with the related molecules found in our study, are depicted in Figures 1a. For the validation we selected a protein for each category by considering both fold variation and the P-value of proteins from the proteomics analysis (see Supplementary Results 2 and Supplementary Tables S2).

Expression of biomarkers in WS
We selected three mitochondrial proteins for the validation on WS—ACON, ATPB and MDHM. First of all, we assessed whether their variation in CFS with respect to control was confirmed in WS of the twin brothers. As depicted in Figure 1b, the upregulation in CFS was corroborated by WB for all the proteins. ACON, ATPB and MDHM showed an increase of 3.1, 1.5 and 4.7, with a significant P-value of 0.006, 0.04 and 0.003, respectively (Table 3).

Thereafter, we moved to the analysis of these proteins in a vast cohort of CFS patients (n = 45) and healthy subjects (n = 45). We started with a global analysis of the expression in WS of these proteins before moving to the examination of different CFS subtypes.

Table 3 and Figure 1c summarize these results. The changes for ACON and ATPB were consistent with the results from nano-LC-MS, but not for MDHM. Then, we classified patients according to their clinical features from questionnaires, that is, we examined the following: FACIT, FIQ, VAS_pain, VAS_fatigue and VAS_sleep. CFS patients were split into two groups considering as reference the twin suffering from CFS. One group with the clinical features whose values were in common with (or greater than) those of the ill twin (group A), and the second with the patients with lower values (group B). Intensities were higher for each of the three markers in group A with respect to group B (Figure 2). Details are given in SR3.
ROC curves

ROC curves were calculated to assess the clinical potential of our selected and validated proteins to distinguish CFS from healthy subjects in WS. The AUCs were calculated for each protein individually, showing whether each marker alone can discriminate CFS from healthy subjects. ATPB and ACON were better differentiating biomarkers than MDHM. ATPB had an AUC of 0.700, with sensitivity = 54% and specificity = 78%. ACON had an AUC of 0.738, with sensitivity = 61% and specificity = 78%. Moreover, using a logistic regression analysis, we investigated whether the discriminative power of each marker could be potentially increased with the combination of various markers. With this purpose, we tested all the different combinations in order to select the best association of biomarkers useful to discriminate CFS from healthy subjects. Thus, we found that the discriminative power slightly increased if ATPB was combined with ACON, as shown in Figure 1d. Indeed, the AUC increased to 0.793 and the sensitivity to 85%, but the specificity was 72%. Finally, we also calculated ROC curves for testing the ability of biomarkers to differentiate patients from controls according to the clinical parameters—only FACIT gave good results. When we split patients according to FACIT, for ATPB and ACON we obtained a ROC curve (group A versus controls) with an AUC of 0.780 and 0.722, respectively, whereas the combined ROC curve had an AUC of 0.844 (sensitivity = 93% and specificity = 70%).

Clinical correlations

Finally, statistical correlations were carried out calculating the Spearman’s rank correlation coefficient. The considered clinical parameters were as follows: age, age of onset, duration of disease and the hematocellular parameters (for example, TNF-α, IL-6 and so on; see the ‘Patients’ section). ACON correlated negatively with IL-2, with a Spearman’s rank correlation coefficient of −0.458 (P-value = 0.010). The levels of ATPB correlated positively with TNF-α and IFN-γ. The Spearman’s rank correlation coefficient was 0.352 (P-value = 0.048) and 0.516 (P-value = 0.004) for TNF-α and IFN-γ, respectively. MDHM also correlates with TNF-α; coefficient 0.447, P-value = 0.013.
DISCUSSION

The discovery and validation of more objective markers could provide an important support for CFS diagnosis and therapy. As evidence suggests that CFS can be underpinned by mitochondrial dysfunctions, we analyzed mitochondrial proteins obtained from platelets. Platelets were from a couple of monozygotic twins discordant for CFS, which were the subjects of our previous study.20 Nano-LC-MS highlighted the changes in expression of 41 proteins with a \( P \)-value \( < 0.05 \) and fold of difference greater than 2. Among these proteins, we selected for the validation three proteins from each of the three most significant biological functions associated with our proteins pointed out after IPA analysis.

These 3 proteins were: ACON for ‘metabolism of isocitric acid’, ATPB for the ‘metabolism of nucleic-acid component or derivative’. Moreover, validation of our proteins pointed out after IPA analysis.

| Protein | TWIN_CTRL | TWIN_CFS | P-value | Fold CFS/ctrl |
|---------|-----------|----------|---------|---------------|
| ACON    | 0.022 ± 0.004 | 0.068 ± 0.014 | 0.006 | 3.1 |
| ATPB    | 0.019 ± 0.004 | 0.028 ± 0.005 | 0.04  | 1.5 |
| MDHM    | 0.001 ± 0.0002 | 0.005 ± 0.001 | 0.003 | 4.7 |

CTRL CFS P-value Fold CFS/ctrl

| Protein | CFS | TWIN_CTRL | P-value | Fold CFS/ctrl |
|---------|-----|-----------|---------|---------------|
| ACON    | 0.024 ± 0.005 | 0.045 ± 0.009 | 0.02  | 1.9 |
| ATPB    | 0.003 ± 0.001 | 0.014 ± 0.005 | 0.006 | 4.6 |
| MDHM    | 0.0007 ± 0.0002 | 0.001 ± 0.0002 | n.s.  | −1.3 |

Abbreviations: ACON, aconitate hydratase; ATPB, ATP synthase subunit beta; CFS, chronic fatigue syndrome; Ctrl, control; MDHM, malate dehydrogenase; n.s., not significant. Normalized optical density are reported as mean ± s.e.m.
candidate protein biomarkers was restricted by the availability of antibodies that can allow detection of proteins in saliva samples.

Despite this study analyzed only two subjects, the differences of protein expression could be linked to the disease itself, as the twins differed only regarding the presence of CFS. By this way, our study on a couple of twins could permit to focus on some biomarkers that can be searched in a wide number of patients in order to confirm their usefulness in CFS diagnosis. We decided to explore the WS of CFS patients preferring to adopt a less invasive procedure in collecting the samples. Although WS is a less complex fluid, it has been proven to be a promising diagnostic tool, which reflects the physiological function of the body. First of all, it was mandatory to check whether the significant increase of these proteins in CFS, with respect to control, could be verified in WS of the twins brothers. Actually, we confirmed the results from nano-LC-MS.

The pathway analysis highlighted the ‘metabolism of NADH’ as one of the most important biological functions involved in CFS. The NAD+/NADH ratio has an omnipresent role in regulating the most important biological functions involved in CFS. The NAD+/NADH ratio has an omnipresent role in regulating the metabolic state. Some studies suggest that NADH concentrations are significantly lower in CFS patients compared with healthy controls. It is likely that high levels of MDHM and isocitrate dehydrogenase observed in CFS may be an adaptive change to deficiencies of NADH which, in turn, has a critical role in mitochondrial ATP production.

ATPB is the subunit beta of the ATP synthase, the key enzyme for ATP production. In addition to the increase of ATPB in CFS, we also detected significant increases of both subunits alpha and gamma using nano-LC-MS (P-value of 0.005 and 0.001 respectively; Supplementary Table S1). Tiredness and energy are tightly connected; therefore, an attractive hypothesis is that there is a metabolic dysfunction with the result that enough energy is not being produced. In this perspective the increase can be explained as an attempt to increase the ATP production. Indeed, there are studies suggesting that the decrease in mitochondrial ATP synthesis in CFS patients is not caused by a defect in the enzyme complexes catalyzing oxidative phosphorylation, but in another factor. In order for ADP to be recycled, and for ATP to pass into the cytosol from the matrix, the exchange of cytoplasmic ADP with mitochondrial ATP across the mitochondrial inner membrane is needed. This function is provided by a translocator protein. Consistent with other lines of work, mitochondrial ADP/ATP translocase expression is modified in our study: translocase 2 and 3 decreased in CFS (P-value = 0.009 and 0.002, respectively; Supplementary Table S1).

Together with ATPB, the most promising biomarker seems to be ACON. This is the mitochondrial form of aconitate, an enzyme that catalyses the stereo-specific isomerization of citrate to isocitrate via cis-aconitate in the tricarboxylic acid cycle. ACON is commonly used as a biomarker for oxidative stress and has been suggested to serve as a sensor of redox status. Indeed, the reaction between ACON and superoxide generates free hydroxyl radical. It is likely that the reaction between superoxide and ACON may enhance mitochondrial oxidative damage associated with the pathophysiology of CFS. As a matter of fact, the excessive production of ROS and nitrogen species is usually related to CFS, and we found a significant upregulation of superoxide dismutase (P-value = 0.0007; Table 2).

After the validation on the WS of twins, we have broadened the validation to a big cohort of CFS patients. Results for ATPB and ACON corroborated the upregulation in CFS, and their clinical potential to discriminate patients from controls was evaluated. ROC curves highlighted good levels of specificity but low sensitivity. If the biomarkers were combined, we obtained a better performance in diagnosis, and the sensitivity increased to 85%, despite a little decrease in specificity.

On the other hand, the MDHM alteration found in twins was not confirmed in the global cohort of patients, but we could observe its increase when we considered only the patients who had similar or higher clinical parameter values than the twin affected by CFS. This finding brought us to inspect whether other putative biomarkers could also demarcate distinct CFS subgroups, seeing the great variability of clinical features of our patients as demonstrated by Table 1. Therefore, we have amplified our analysis looking closely at clinical data, with the specific aim to investigate how the biomarkers were linked with patients’ clinical characteristics. We analyzed the expression of our proteins after
splitting patients according to clinical parameters. For each marker, the values were actually higher in the group of patients who had clinical features similar to the ill twin. It seemed that the increase in expression of these proteins was corresponding to a worse patient outcome.

In addition, the combination of ATPB with ACON gave a ROC curve with sensitivity of 93% and specificity of 70%, when we checked patients with values of FACIT greater than equal to those of CFS twin.

It is noteworthy also to point out that CFS patients with comorbid bipolar disorder, and not with other psychiatric comorbidities, showed a significant upregulation of ATPB expression (P-value = 0.03, data not shown). In our cohort of patients only eight CFS patients had comorbid bipolar disorder (Table 1); anyway, this aspect deserves future investigation, considering that hampered mitochondrial function in bipolar patients has been reviewed.19,50

Finally, we investigated the correlation of our proteins with hematological parameters. Cytokine abnormalities are common in CFS, but the findings are mixed and no individual marker is used as an objective biomarker for the diagnosis or management of CFS. It is noteworthy that the increase of ATPB in CFS correlated positively with the increase in IFN-γ and TNF-α. Immunological dysregulation has been always proposed as a significant component of the CFS, and CFS patients usually have high levels of pro-inflammatory cytokines, such as IFN-γ and TNF-α.14,51,52 In addition, MDHM correlated positively with TNF-α. These correlations are instructive, as all these variables can be thought as markers as it is interesting to point out that ACON levels correlated negatively with IL-2, in line with the fact that the twin with CFS had lower levels of IL-2 with respect to his healthy twin brother.20

In conclusion, these results suggest that our potential markers could be one of the criteria to be taken into account for helping in diagnosis. Furthermore, even if these proteins may not necessarily be useful for a universal diagnosis of CFS, given the huge heterogeneity of the illness, they offer a strong potential for characterizing subsets. The identification of biomarkers present in particular subgroups of CFS patients may help in shedding light upon the complex entity of CFS. Moreover, it could help in developing tailored treatments.

By this way, this work may contribute to the continuous development of a more clear framework for a complex and nuanced disease such as CFS.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
This work has been supported by the Italian ‘Fondazione Itita’ onlus with the ‘Premio di Mobilità Itita, 2014’ given to FC. UK, RPZ and AS gratefully acknowledge the financial support by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin and the Bundesministerium für Bildung und Forschung.REFERENCES

1 Werker CL, Nijhof SL, van de Putte EM. Clinical Practice: chronic fatigue syndrome. Eur J Pediatr 2013; 172: 1293–1298.
2 Yancey JR, Thomas SM. Chronic fatigue syndrome: diagnosis and treatment. Am Fam Physician. 2012; 86: 741–746.
3 Carruthers BM, van de Sande MT, De Meirleir KL, Klimas NG, Broderick G, Mitchell T et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med 2011; 270: 327–338.
4 Johnston S, Brenu EW, Staines D, Marshall-Gradiski S. The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis. Clin Epidemiol 2013; 5: 105–110.
5 Bruberg KG, Fanhus MS, Larun L, Flottorp S, Malterud K. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open 2014; 4: e003973.
6 Bakken I, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Torgstad L et al. Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008–2012. BMC Med 2014; 12: 167.
7 Pheby D, Sneddon P, Heinrich I. Severe ME/CFS in adults - a report from the CHROME database. Bull IACFS/ME 2009; 17: 143–167.
8 Donegan K, Beau-Lejdstrom R, King B, Seabrooke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine 2013; 31: 4961–4967.
9 Rosenblum H, Shoenfeld Y, Armital N. The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. Infect Dis Clin North Am 2013; 25: 851–863.
10 Magnus P, Brubakk O, Nyland H, Wold BH, Gjesing HK, Brandt I et al. Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome. Vaccine 2009; 27: 23–27.
11 Shapiro JS. Does varicella-zoster virus infection of the peripheral ganglia cause chronic fatigue syndrome? Med Hypotheses 2009; 73: 728–734.
12 Exley C, Struehr B, Gherardi RK, Aufrichtig F. A role for the body burden of aluminum in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses 2009; 72: 135–139.
13 Nij S, Nees A, Paul L, De Koning M, Ickmans K, Meese M et al. Altered immune response to exercise in patients with chronic fatigue syndrome/myalgic encephalomyelitis: a systematic literature review. Exerc Immunol Rev 2014; 20: 94–116.
14 Brenu EW, Huth TK, Hardacre SL, Fuller K, Kaur M, Johnston S et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol 2014; 26: 233–242.
15 Armstrong CW, McGregor NR, Buttl HL, Gooley PR. Metabolism in chronic fatigue syndrome. Adv Clin Chem 2014; 66: 121–172.
16 Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immune-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis 2014; 29: 19–36.
17 Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int J Clin Exp Med 2012; 5: 208–220.
18 Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009; 2: 1–16.
19 Gorman GS, Elson JL, Newman J, Payne B, McFarland R, Newton JL et al. Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease. Neuromuscul Disord 2015; 25: 563–566.
20 Ciregia F, Giuslì G, Da Valle Y, Donadio E, Consensi A, Giacomelli C et al. A multidisciplinary approach to study a couple of monozygotic twins discordant for the chronic fatigue syndrome: a focus on potential salivary biomarkers. J Transl Med 2013; 11: 243.
21 Garcia-Souza LF, Oliveira MF. Mitochondria: biological roles in platelet physiology and pathology. Int J Biochem Cell Biol 2014; 50: 156–160.
22 Zharkov S, Shiva S. Platelet mitochondrial function: from regulation of thrombosis to biomarker of disease. Biochem Soc Trans 2013; 41: 118–123.
23 Burkhardt JM, Vaudel M, Gambaryan S, Radua S, Walter U, Martens L et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012; 120: e73–e82.
24 Gründler K, Angstwurm M, Hilge R, Baumann P, Annecke T, Crispin A et al. Platelet mitochondrial membrane depolarization reflects disease severity in patients with sepsis and correlates with clinical outcome. Crit Care 2014; 18: R31.
25 Silva AC, Almeida S, Duarte AI, Domingues J, Oliveira CR et al. Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington’s disease carriers. Mitochondrion 2013; 13: 801–809.
26 Carelli V, Ghelli A, Ratta M, Bacchilega E, Sangiorgi S, Mancini R et al. Leber’s hereditary optic neuropathy: biochemical effect of 11778 ND4 and 3460 ND1 mutations and correlation with the mitochondrial genotype. Neurology 1997; 48: 1633–1637.
27 Mann VM, Cooper JM, Krieg D, Daniel SE, Schapira AH, Marsden CD. Brain skeletal muscle and platelet homogenate mitochondrial function in Parkinson’s disease. Brain 1992; 115: 333–342.
28 Tang WH, Stitham J, Jin Y, Liu R, Lee SH, Du J et al. Amodine reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation 2014; 129: 1598–1609.
29 Avila C, Huang RJ, Stevens MV, Aponte AM, Tripodi D, Kim KY et al. Platelet mitochondrial dysfunction is evident in type 2 diabetes in association with modifications of mitochondrial anti-oxidant stress proteins. Exp Clin Endocrinol Diabetes 2012; 120: 248–251.

Translational Psychiatry (2016), 1 – 9
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)